Zensun’s Neucardin HF drug is fast-tracked by the FDA. Neucardin is a recombinant...
Matinas BioPharma’s upcoming Phase II initiation may open door to prescription omega fatty acid space
MAT9001 is being developed for therapeutic applications in the dyslipidemia field and is targeting severe hypertriglyceridemia as its primary indication.
Novartis still hoping for Entresto success in heart failure with preserved ejection fraction
At ESC 2019, Novartis gave insight into the unsuccessful results of the PARAGON-HF trial for heart failure with preserved ejection fraction (HF-PEF).
Esperion’s cholesterol-lowering drug has positive Phase II results for Type 2 diabetes patients
The drug combination was shown to significantly lower LDL-C by 40% compared to placebo and reduce high-sensitivity C-reactive protein.
AstraZeneca’s Brilinta reduces CV events risk in Themis trial
AstraZeneca has reported positive results from the Phase III Themis clinical trial conducted to assess the combination of Brilinta (ticagrelor) with aspirin in coronary artery disease and type-2 diabetes patients.
Medicines Company’s cholesterol drug inclisiran meets Phase III goals
The Medicines Company has announced that inclisiran met all primary and secondary efficacy endpoints in the Phase III ORION-11 clinical trial for lowering LDL-cholesterol (LDL-C).
MyoKardia starts dosing hypertrophic cardiomyopathy patients
MyoKardia has commenced dosing of patients in a Phase I trial of small molecule MYK-224 for the treatment of hypertrophic cardiomyopathy (HCM).
Farxiga meets primary goal in Phase III heart failure trial
AstraZeneca’s Farxiga (dapagliflozin) has met the primary endpoint in Phase III DAPA-HF study involving patients with reduced ejection fraction (HFrEF), with or without type 2 diabetes.
Medable to enhance digital real-world evidence research network
US-based data-driven clinical trials provider Medable is set to join the American Heart Association’s Center for Health Technology & Innovation Innovators Network to improve a patient-centric digital system that connects patients and researchers.